decisionhealth Newsletters, Coder Pink Sheets - 2007 Issue 3 (March)
Note last-minute change to osteoarthritis drug code
Subscribe or sign in to view the full article.
Article Overview
This article explains a late 2007 Medicare-related HCPCS update involving billing for hyaluronan injections, with attention to how different payers may recognize different drug codes. It is useful for physicians, coders, and billing staff who work with orthopedic or primary care osteoarthritis services and need to track quarterly drug fee schedule changes and related CMS guidance.
Why This Topic Matters
Coverage and billing rules for injected osteoarthritis therapies can change quickly, and this update affects how practices report and reimburse a commonly used medication category. Understanding the article helps readers follow payer-specific HCPCS reporting changes tied to the 2007 ASP drug pricing update.
Article Sections
-
HCPCS update for hyaluronan injections
Summarizes the article’s focus on a late code change affecting billing for hyaluronan injections and the payer-specific context for the update.
-
Medicare quarterly drug fee schedule change
Describes the Medicare-related revision referenced in the quarterly drug pricing update and the broader HCPCS framework involved.
-
Drug product mapping
Lists the hyaluronan products associated with the codes discussed in the article.
What You Will Learn
- The general nature of the HCPCS change affecting hyaluronan injection billing
- How Medicare’s quarterly drug pricing update relates to reporting of these injections
- Which organizations and payer contexts are discussed in connection with the update
- How the article connects product names to the codes referenced
Who Should Read This
- Physicians
- Medical coders
- Billing staff
- Orthopedic practices
- Primary care practices
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com